Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
about
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancerEarly-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemAdjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineApplication of marginal structural models in pharmacoepidemiologic studies: a systematic review.Status of adjuvant endocrine therapy for breast cancer.Estimating efficacy in trials with selective crossover.Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.Polymorphism at 19q13.41 Predicts Breast Cancer Survival Specifically after Endocrine Therapy.Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's ChoicesAdjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.Endothelin-1 enriched tumor phenotype predicts breast cancer recurrence.Hormonal therapies in young breast cancer patients: when, what and for how long?Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study.Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersBone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.Providers of follow-up care in a population-based sample of breast cancer survivors.How do I follow patients with early breast cancer after completing adjuvant therapy.The optimal duration of adjuvant endocrine therapy for early stage breast cancer--with what drugs and for how long?Inconsistent selection and definition of local and regional endpoints in breast cancer research.The UZ Leuven Policy for Extended Adjuvant Anti-estrogen Therapy in Women With Early Estrogen Receptor-Positive Breast Cancer.New insights into endocrine therapy for young women with breast cancer.Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.Extended Endocrine Therapy: Is 5 Years Enough?Does patient education work in breast cancer? Final results from the global CARIATIDE study.Screening MRI in Women With a Personal History of Breast Cancer.A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression.An unmet need: tailoring extended adjuvant endocrine therapy.A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation.Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials.Searching for the IDEAL Duration of Adjuvant Endocrine Therapy.Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling.Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.
P2860
Q26782494-73C43B9E-B187-4AAA-8F57-4A99ED3C2F15Q26782584-85F27C69-1ED9-4DFE-9B50-6B7289766256Q27002430-BFB8E2EA-2A15-40A5-8F74-AF3E984D97DEQ33707284-DE920643-D538-40A9-89A5-7AA8313926D0Q33739138-C19D0EE2-96FA-44BC-A8D5-55BC52855535Q33835695-23E961E0-1205-41D6-9483-45BF8DBE9D15Q34303205-D0BD074A-6967-4B6E-8676-DAADC02080A7Q35824414-8A0873DF-048E-422A-996F-4EC8082053BAQ35847450-10B38463-D283-424F-8FF1-15ACF5AE17B3Q36071595-DC766737-207A-4AD8-923B-4CF8E0352CB7Q36322870-855A5785-28C2-4D46-B5C3-8BE61F2C9A1CQ36469983-3D6164E0-137A-403A-AF47-B832A445FFBDQ36788354-ABAC91B1-F35B-4501-8C2D-73FC264DA3C1Q36854062-1CD84AEB-1587-4A10-8C34-D5878F647EB4Q36895055-767DA1A9-92A8-4BFF-98F4-55FDAF2EF1BBQ36959649-3E5D91EB-2C92-4219-9E62-D5ACAB032B36Q36963393-E332BEB2-22C3-4F89-B1E1-8C06B22C6DC2Q37463330-46818769-5F0C-409B-8892-6659D6789CA0Q37559006-97211AD2-921B-4CB5-8C5C-0F5AC954C5DFQ37690351-EE9BCF08-A10C-4036-B08C-AEEF92FB52A9Q37696677-A7DF0345-566A-4CB6-AB51-B055AB37A0E6Q37709416-CEC97F63-1FB2-4238-A914-54897B437C38Q38172001-9615F6D7-31D1-4563-8E70-8D945B281394Q38175883-0661BBF3-A651-4A6B-B86E-D033354C78B2Q38259456-F916D0F7-5453-4CA1-BA95-535E6BB8C072Q38510960-62114D66-6273-4FBC-9858-1A504E1A8236Q38535371-5086FE62-496E-46FD-B990-6BDE5935FAB3Q38635960-ABA16F44-FCB6-4DE7-A4BE-8C5E1B5199CBQ38934318-D8236339-C080-4155-8CDA-D99436759EFEQ39057658-03D04FE0-4CEF-429A-9850-75F7FF1D7ABEQ40130076-E85990A3-A260-4777-95D9-8E60ED23EF7CQ42763247-0439C558-F930-4094-B116-1351850CD89AQ42813847-C62A861A-D489-4D49-91E3-595D06324BC3Q44615442-CB1140D6-6068-4247-B31C-78104E343465Q47994905-4B6C6641-3391-4605-A022-B7E366BC742EQ50042338-3342AEC6-11E9-4E50-97F2-EA3D54A9C4C0Q54942720-53A40BA1-1118-42DB-B287-0A7B7FE24D90Q54987182-408EE28F-B395-49A4-AB09-C8598B1A1A91
P2860
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Longer-term outcomes of letroz ...... sting for treatment crossover.
@ast
Longer-term outcomes of letroz ...... sting for treatment crossover.
@en
type
label
Longer-term outcomes of letroz ...... sting for treatment crossover.
@ast
Longer-term outcomes of letroz ...... sting for treatment crossover.
@en
prefLabel
Longer-term outcomes of letroz ...... sting for treatment crossover.
@ast
Longer-term outcomes of letroz ...... sting for treatment crossover.
@en
P2093
P2860
P356
P1476
Longer-term outcomes of letroz ...... sting for treatment crossover.
@en
P2093
Dongsheng Tu
Lois E Shepherd
Naiqing Zhao
Paul E Goss
P2860
P304
P356
10.1200/JCO.2010.34.4010
P407
P577
2011-10-31T00:00:00Z